Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 11/20 | 0.72 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.66 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.66 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atosiban SCHEMBL34316 | 0.95 | OXTR (0.71) | OXTRAVPR1AAVPR2AVPR1B | |
| Atosiban SCHEMBL19712221 | 0.95 | OXTR (0.71) | OXTRAVPR1AAVPR2AVPR1B | |
| Atosiban SCHEMBL29522709 | 0.95 | OXTR (0.71) | OXTRAVPR1AAVPR2AVPR1B | |
| Atosiban SCHEMBL1648581 | 0.95 | OXTR (0.71) | OXTRAVPR1AAVPR2AVPR1B | |
| Atosiban SCHEMBL4410202 | 0.94 | OXTR (0.69) | OXTRAVPR1AAVPR2AVPR1B | |
| Atosiban SCHEMBL3138542 | 0.93 | OXTR (0.69) | OXTRAVPR1AAVPR2AVPR1B | |
| Atosiban SCHEMBL4414282 | 0.92 | OXTR (0.67) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL15511860 | 0.90 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL14059683 | 0.88 | OXTR (0.78) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL26813594 | 0.85 | OXTR (0.58) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190247361-A1 | OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE | ReproNovo SA (CH) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247361-A1 | OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE | OXTR, PGF, PRLHR | OXTR 1/4885AVPR1A 77/4885AVPR2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.